Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DR. BOND who wrote (2835)	11/26/1997 2:46:00 AM
From: Steve Childs	Read Replies (2) \| Respond to of 23519

This is not directed at you, agent 007, aka, Dr. Bond, it's directed to the PFE lovers: YOU GOT THE WRONG STOCK! If you really want a winner in big cap drug firms, buy LLY. Now THERE'S a winner. Better valuation, and their new drug for osteoporosis should be a blockbuster. Great pipeline. Pfizer's proper valuation is around $65. LLY's is also around $65-70. Look at the prices, and then pick one. I'd pick osteoporosis over impotence, since Lilly doesn't have a 'Vivus' competing against it, as PFE does, does it?